These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22451454)

  • 1. Comments on 'Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design' by Satoshi Morita and Junichi Sakamoto. Pharmaceutical Statistics.
    Hossain MM; Chen Z
    Pharm Stat; 2012; 11(3):267-8. PubMed ID: 22451454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design.
    Morita S; Sakamoto J
    Pharm Stat; 2006; 5(2):109-18. PubMed ID: 17080767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary on 'accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimized multi-arm phase I/II trial design'.
    Dixon D
    Trials; 2014 Mar; 15():76. PubMed ID: 24628806
    [No Abstract]   [Full Text] [Related]  

  • 4. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
    Yada S; Hamada C
    Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines.
    Mistry P; Dunn JA; Marshall A
    BMC Med Res Methodol; 2017 Jul; 17(1):108. PubMed ID: 28720094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trials: inevitable or inadvisable?
    Gan HK; Grothey A; Pond GR; Moore MJ; Siu LL; Sargent D
    J Clin Oncol; 2010 May; 28(15):2641-7. PubMed ID: 20406933
    [No Abstract]   [Full Text] [Related]  

  • 8. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
    Ratain MJ; Karrison TG
    Clin Cancer Res; 2007 Feb; 13(3):781-2. PubMed ID: 17289865
    [No Abstract]   [Full Text] [Related]  

  • 9. An adaptive design for phase II non-oncology dose selection clinical trials.
    Su Z
    Clin Drug Investig; 2010; 30(6):397-403. PubMed ID: 20373828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
    Xie F; Ji Y; Tremmel L
    Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General keynote: clinical trial design.
    Berry DA
    Gynecol Oncol; 2003 Jan; 88(1 Pt 2):S114-6; S122-3. PubMed ID: 12586099
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimal two-stage randomized phase II clinical trials.
    Logan BR
    Clin Trials; 2005; 2(1):5-12. PubMed ID: 16279574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of adaptive designs for single-armed phase II oncology trials.
    Kieser M; Englert S
    J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive seamless designs with interim treatment selection: a case study in oncology.
    Carreras M; Gutjahr G; Brannath W
    Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 18. Specific keynote: clinical trial design problems in ovarian cancer.
    Stevenson A; Gore M
    Gynecol Oncol; 2003 Jan; 88(1 Pt 2):S117-21; discussion S122-3. PubMed ID: 12586100
    [No Abstract]   [Full Text] [Related]  

  • 19. Newer phase II trial designs gaining ground.
    Benowitz S
    J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
    [No Abstract]   [Full Text] [Related]  

  • 20. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.